Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
Study to evaluate early glatiramer acetate treatment in delaying conversion to CDMS of subjects presenting with CIS (PreCISe)
Cyclophosphamide
HL-A antigens and multiple sclerosis.
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
ALSUntangled No. 8: Low dose naltrexone for ALS.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Binding of recombinant T cell receptor ligands (RTL) to antigen presenting cells prevents upregulation of CD11b and inhibits T cell activation and transfer of experimental autoimmune encephalomyelitis.
Study hints of rituximab MS benefit
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
Signal Transduction in the Blood-Brain Barriers
Reactive astrocytes as therapeutic targets for CNS disorders.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Ofatumumab
Immunology 2013
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Daclizumab for relapsing remitting multiple sclerosis.
Pharmacokinetic properties and metabolism of idebenone.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.

Pages